In this video, Dr. Keith Ferdinand, Chief Science Officer of the Association of Black Cardiologists, talked about heart disease and atrial fibrillation among minorities, especially blacks and African Americans. He talked about why blacks appear to have less afib than whites, and what blacks should be doing to prevent AF and heart disease. Watch the …
Read More
In this video, Dr. Matthew Reynolds, of the Harvard Clinical Research Institute, discussed his quality of life findings from use of catheter ablation and antiarrhythmic drugs for treatment of atrial fibrillation. He analyzed quality of life data that was collected as part of the THERMOCOOL catheter trial in which catheter ablation was found to be …
Read More
watchLAB is hosting a market research study in Los Angeles, Pittsburgh and Seattle with Atrial Fibrillation patients who have experienced both chemical (IV) and electrical cardioversion, preferably in the past 2 years. If you qualify, you will be invited to participate in a one hour interview or a small 1.5-hour group discussion to share your …
Read More
You're invited to join AF Stat™: A Call to Action for Atrial Fibrillation for the unveiling of the results of AFib in America: State Impact Reports. This first-of-its-kind analysis will feature state level statistics and resources related to the burden of atrial fibrillation (AFib) across the nation. To learn more, see: AF Stat Coalition to …
Read More
You're invited to join us for the launch of The Silver Book®: Thrombosis on March 23, 2011, at the Rayburn House Office Building on Capitol Hill in Washington, DC. If you can't make it, see how you can order a copy of the book, which features statistics on atrial fibrillation and strokes. See: Atrial Fibrillation …
Read More
Mellanie True Hills, founder and CEO of StopAfib.org and an atrial fibrillation survivor, is an invited speaker for the Fourth Annual Western Atrial Fibrillation Symposium taking place February 25-26, 2011 in Park City, UT. Symposium Director Dr. Nassir F. Marrouche says, " For the first time, the faculty includes someone representing the patients." Learn more: …
Read More
Note: In meetings with the FDA last week, representatives from WomenHeart and StopAfib.org became aware of the risk that potential funding cuts may significantly delay the FDA's work in reviewing and approving afib drugs and devices. Because of the potential impact on the afib community, we are publishing comments from WomenHeart as to what those …
Read More
Researchers at the Comprehensive Arrhythmia Research and Management Center (CARMA) in Utah have been studying the relationship between atrial fibrillation, atrial fibrosis, and catheter ablation outcomes for many years. Now, they’ve applied their knowledge of quantifying atrial fibrosis to stroke risk assessment and found that the amount of atrial fibrosis, not type of afib, is …
Read More
New research from Denmark shows that CHADS2 underestimates stroke risk. In the study, atrial fibrillation patients who were at intermediate risk with the CHADS2 scoring system had more than twice the stroke rate of those defined by the enhanced CHA2DS2-VASc tool as being at intermediate risk. While CHADS2 deemed 32.3% of patients to have intermediate …
Read More
In this video, Dr. Kenneth Ellenbogen talks about important information presented at the American Heart Association Scientific Sessions 2010. First he talked about the ROCKET AF clinical trial of rivaroxaban, a new drug that is an alternative to warfarin (Coumadin), as well as another alternative, the recently-approved dabigatran. He provided scenarios as to how these drugs …
Read More